Hemophagocytic lymphohistiocytosis in a patient with Sjögren’s syndrome: case report and review

L. García-Montoya1 · C. N. Sáenz-Tenorio1 · I. Janta1 · J. Menárguez1 · F. J. López-Longo1 · I. Monteagudo1 · E. Naredo1

Received: 28 July 2016 / Accepted: 4 November 2016 / Published online: 16 November 2016
© Springer-Verlag Berlin Heidelberg 2016

Abstract Hemophagocytic lymphohistiocytosis (HLH) is a very rare syndrome with a mortality up to 95% of cases if not treated. It is characterised by an excessive activation of the immune system that leads to a disproportionate and destructive inflammatory response. The high mortality rates are in part due to a delay in the diagnosis, and therefore clinicians must maintain a high index of suspicion. When the treatment is started early, the survival rate reaches around 55% of cases. HLH usually presents with persistent fever, pancytopenia, and organomegaly and is associated with very high levels of serum ferritin. In this manuscript, we present the case of a patient with primary Sjögren’s syndrome who developed HLH after an acute infection by Cytomegalovirus. We will describe and discuss the pathogenesis, differential diagnosis and a pragmatic approach to the treatment for this critically important and, when diagnosed early, potentially curable syndrome.

Keywords Hemophagocytic lymphohistiocytosis · HLH · Sjögren’s syndrome · Cytomegalovirus · CMV

Case report

A 70-year-old woman was admitted to the emergency department presenting with a fever of 39 °C, asthenia, a dry cough and rapid weight loss of 2 kg within 12 days. Her previous medical history consisted of systemic hypertension controlled with valsartan.

The physical examination (including cardiorespiratory, gastrointestinal, lymph nodes and ear, nose and throat) did not reveal any abnormalities. Initial laboratory studies revealed leukocytosis, thrombocytopenia, hypertransaminasemia and hypertriglyceridemia in addition to elevated lactate dehydrogenase (LDH), serum ferritin, uricemia and C reactive protein (CRP) levels. The chest radiograph was normal with no focal abnormality. The urinalysis was normal with no active renal sediment.

The patient was hospitalized with a clinical diagnosis of an atypical lower respiratory infection. Blood cultures were extracted, and she was commenced on levofloxacin 500 mg intravenous (i/v) every 24 h. Despite several days of treatment, her fever persisted with no specific pattern and no rash was observed. Laboratory tests worsened with the development of normocytic normochromic anemia, low serum fibrinogen and a deterioration of renal function. Fibrinogen 1 g every 12 h had to be administered. Serological tests were performed in order to rule out infection by atypical bacteria or viruses [Brucella, Coxiella, Mycobacterium tuberculosis, Mycobacterium avium, Borrelia, Leishmania, hepatitis A, B and C (VHA, VHB, VHC), human immunodeficiency virus (HIV), Cytomegalovirus (CMV) and Epstein–Barr Virus (EBV)].

The chest, abdomen and pelvic computer tomography (CT) scans and the abdominal ultrasound (US) revealed mild hepatosplenomegaly in the absence of swollen lymph nodes or tumor.

The rheumatology department requested a complete immunology assessment when the patient reported a history of several years of eye and mouth dryness. Adult Still’s disease and HLH were also considered in the differential diagnosis due to high levels of ferritin (58,300 ng/mL) although the patient did not disclose a history of arthralgias or skin rash. The hematology department performed
a bone marrow biopsy which revealed hemophagocytosis, plasmacytosis and no signs of malignancy, findings consistent with HLH. The serology and microbiology tests were negative for all the previously described infectious agents, except for elevated CMV immunoglobulin M (IgM) antibodies and a viral load of 27,400 copies.

The final diagnosis was HLH triggered by an acute CMV infection, and intravenous (IV) ganciclovir (5 mg/kg/day) was started on the 10th day of hospitalization. After 2 weeks of treatment, the patient felt better and every altered parameter had normalized (Table 1). The viral load decreased to 2300 copies (Fig. 1). When the microbiology department considered that the infection was controlled, immunosuppressive treatment with i/v methylprednisolone 500 mg/day was administered for 3 days, followed by cyclosporine 6 mg/kg/day.

The patient was discharged from the hospital 4 weeks after admission. Immunology tests performed at admission were positive for anti-Ro and anti-La antibodies. A salivary glands gammagraphy, Schirmer’s test and a biopsy of the salivary glands confirmed the suspicion of pSS and treatment was initiated with hydroxychloroquine 200 mg every 12 h orally and saline eye drops. The rest of the immunologic assessment was negative, including genetic mutations.

We describe the main primary autoimmune conditions (including pSS) and a number of infectious agents (including CMV) that are recognized causes of HLH. However, there seems to be an underlying alteration in the immunity (might be identified or not) that is always working as the predisposing factor.

Discussion

HLH is a life-threatening condition consisting of an excessive immune activation. It is essential to consider this diagnosis because the mortality rate can be up to 95% without treatment, and a delay also worsens the prognosis, as the median survival time without treatment is 2 months [1]. It was first described in 1939 but the knowledge about this syndrome is still quite limited due to the small sample size of patients, which makes a study extremely challenging [2]. It presents in patients of all ages, more commonly in children. No data are available concerning its global prevalence. Primary forms of HLH usually appear within the first 3 months of life, and it is equally present in both genders.

Table 1  Blood parameters

|                         | At arrival | 1 Week after admission | After treatment | Reference value |
|-------------------------|------------|------------------------|-----------------|----------------|
| Hemoglobin              | 12.2       | 10.7                   | 13.3            | 12–16 g/dL      |
| Platelets               | 107,000    | 77,000                 | 184,000         | 140,000–400,000 IU/μL |
| Leukocytes              | 13,800     | 7500                   | 9500            | 4000–10,000 IU/μL |
| ALT                     | 99         | 115                    | 19              | 5–31 IU/L       |
| AST                     | 64         | 145                    | 27              | 10–31 IU/L      |
| GGT                     | 37         | 96                     | 12              | 6–40 IU/L       |
| LDH                     | 578        | 176                    | 135–214 IU/L    |
| Alkaline phosphatase    | 91         | 140                    | 68              | 35–105 IU/L     |
| Triglycerides           | 225        | 259                    | 124             | 50–150 mg/dL    |
| Fibrinogen              | 273        | 56                     | 213             | 150–450 mg/dL   |
| C reactive protein      | 2.3        | 24.4                   | 0.5             | 0–0.5 mg/dL     |
| Ferritin                | 58,281     | 135                    | 12–200 μg/L     |
| Uric acid               | 9.8        | 5.2                    | 2.4–6 mg/dL     |
| Creatinine              | 1.34       | 1.71                   | 0.72            | 0.5–0.9 mg/dL   |
| Glomerular filtration   | 39         | 29                     | >60             | >60 mL/min/1.73 m² |

ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma glutamyl transferase, LDH lactate dehydrogenase

Fig. 1  Evolution of the viral load once the treatment was started. CMV cytomegalovirus
The underlying cause of this syndrome is an alteration of the perforin-dependent cytotoxicity [5]. It can consist of one single episode or be a relapsing disease. There is an excessive secretion of cytokines by macrophages (cytokine storm) and an impairment of the natural killer (NK) cells. On the other hand, macrophages literally “eat” blood cells. This process can be observed in the bone marrow (as in our patient) lymph nodes, spleen and liver biopsies [6–8].

There are two forms of primary HLH: Familial hemophagocytic lymphohistiocytosis, which tends to present at a young age (70% in children under 1 year old and 14% in adults) [9–12] and genetic immunodeficiency syndromes [i.e., Griscelli Sd, Chediak–Higashi and Hermansky–Pudlak syndromes, XMEN (“X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasia”), X-linked lymphoproliferative and chronic granulomatous diseases] [13–18].

Sepulveda et al. [19] carried out an observational study with mice and suggested that primary inherited forms of HLH could be caused by bi-allelic mutations in genes coding perforin-dependent cytotoxicity.

Secondary forms of HLH are associated with infections, malignancies (essentially lymphoma, leukemia and myelodysplasia) [20, 21], acquired immunodeficiency and macrophage activation syndrome (MAS). When infections are involved, the trigger is usually a microorganism with an intracellular replicative cycle and systemic bacteria. Our patient was infected by CMV, but other viral triggers have been described such as EBV, HIV, VHA, VHB, VCH, human perpesvirus, varicella zoster, herpes simplex, influenza and parainfluenza and measles virus. Some examples of bacterial etiologies are mycobacteria, Brucella, Rickettsia, Hemophilus influenzae and Serratia sp. The most common parasites are Leishmania and Toxoplasma [22–30].

Sepulveda et al. [19] also reported that a small number of patients with a secondary form of HLH were carriers of a monoallelic mutation of one or more genes associated with HLH; however, the results pointed toward a polygenic inheritance.

Macrophage activation syndrome is considered to be a special form of secondary HLH that occurs in patients with an underlying autoimmune disease. It is also known as “reactive hemophagocytic syndrome” and has a mortality rate of up to 50% [31]. Of all HLH cases, 5% present as such and our patient was one of those. The debut of a systemic disease might be the only underlying cause in developing HLH. However, some rheumatic diseases only play a role as a predisposing factor and in fact need an infection to work as a trigger [32–34]. Our patient probably suffered from Sjögren’s syndrome for several years before the diagnosis and the infection by CMV could have been the trigger.

As far as the clinical manifestations are concerned, the first and one of the most prevalent symptoms is fever, which appears in 93% of patients as a result of high levels of interleukins. The unrelenting fever is usually what makes the patient seek medical help. No fever pattern has been identified, but body temperature can reach up to 40 °C. Splenomegaly is secondary to lymphocytic and macrophagic infiltration and appears in 96% of patients. Hepatomegaly is present in 95% of cases. Lymphadenopathy, neurological alterations and skin rashes are only found in 30% of HLH cases [35].

The lack of specificity of the clinical features is precisely what makes this syndrome so hard to diagnose. It can simulate common diseases such as hepatitis or encephalitis. The underlying genetic alteration does not cause different symptoms, except for a few exceptions, which are related to specific manifestations besides the common ones [36, 37].

Neurological involvement is quite variable and can be as mild as a headache or as severe as ataxia or a demyelinating pathology. There is also an increased risk of encephalopathy, which is reversible in most cases, consisting of headache, low consciousness and visual impairment. Patients may present hypodense or necrotic areas on a magnetic resonance imaging (MRI) and up to half of them have abnormalities in the cerebrospinal fluid (CSF) [38].

Other possible manifestations are acute respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), bleeding or renal dysfunction [35, 39].

Concerning the laboratory findings, cytopenias are seen in 75% of patients and can be explained by high concentrations of α-tumor necrosis factor (TNF-α) and interferon. The final platelet count is usually the most affected with an average of 70,000 U/µL. Hemoglobin can decrease as low as 3 g/dL [40]. Serum ferritin levels tend to be higher than expected for an acute phase reactant and remain between 500 and 10,000 ng/mL. Children tend to present higher concentrations (levels >10,000 ng/mL have a specificity of 95%) in contrast to adults, whose levels usually remain around 2000 ng/mL. Older patients are also likely to suffer from other causes that can justify this elevation, such as concomitant infections, sepsis or organ failure, which makes hyperferritinemia less specific. It is important to remember that macrophages are a source of ferritin, which clearly explains the link [1, 37].

Hepatic function is altered, which often can mimic hepatitis. Transaminases are elevated as well as lactate dehydrogenase (LDH) and alkaline phosphatase (AP). High triglycerides are secondary to an increase in the levels of TNF-α and a lower activity of lipoprotein lipase. As hepatic function is impaired, hypofibrinogenemia is common and coagulation...
times can be prolonged sometimes leading to disseminated intravascular coagulation (DIC). Our patient presented several of these alterations; however, once the treatment was started, all parameters normalized rapidly [37, 41].

In order to make an early diagnosis, it is essential to assess any organ involvement with a full physical examination and ancillary laboratory and diagnostic imaging tests. Overlapping infections or conditions should be ruled out. Once the patient is stable, a complete familial history should be performed. Initial evaluations should include a blood count, coagulation panel, serum ferritin levels, urinalysis, liver and kidney function, urine and blood cultures, a chest radiograph and an electrocardiogram. In order to evaluate multiple organ damage, it might also be necessary to perform an echocardiogram, a bone marrow aspirate, a lumbar puncture, a brain magnetic resonance imaging and a body CT scan [37].

Bone marrow aspiration and a biopsy are useful to investigate the cause for cytopenia, as well as to rule out infections or malignancy. The findings of hemophagocytosis and activated macrophages with a benign appearance are consistent with HLH but not pathognomonic. However, in cases of high suspicion and a negative result, a liver, spleen, skin or lymph node biopsies are justified. The lack of macrophagic invasion does not rule out HLH; the following conditions can be responsible for a false negative: an early biopsy before the disease has produced an infiltrative process; the administration of immunosuppressive therapies; and a recent blood transfusion [42, 43].

The immunologic assessment includes levels of soluble IL-2 receptor-α (they correlate with the degree of disease activity), NK cell function/degranulation and flow cytometry for cell surface expression of serum amyloid P component (SAP) and X-linked inhibitor of apoptosis protein (XIAP) in males. Genetic and HLA testing should be performed if available. Our patient was negative for mutations in perforin 1 (pore-forming protein) (PRF1), protein unc-13 homolog D (UNC13D), syntaxin 11 (STX11) and syntaxin binding protein 2 (STXBP2) genes and NK cytotoxic activity. The existence of other mutations that are potential causes of HLH is likely; however, most of them have not yet been identified [44–46].

The current diagnostic criteria are based on the HLH trial published in 2004 [47] (Fig. 2). Many patients do not fulfill the criteria but actually suffer severe symptoms; therefore, it is necessary to start them on immunosuppressants as soon as possible. Early treatment is crucial and should not be delayed under any circumstance [1, 43].

It is important to evaluate the patient as a whole, taking into account the clinical context. The main goal is to suppress the severe inflammatory response that might be threatening the patient’s life. Supportive treatment is always required, and it usually consists of prophylactic antibiotics, diligent fluid, electrolyte management and platelet transfusions. The basis of the immunosuppressive treatment includes dexamethasone, etoposide and cyclosporine A.

In addition to this, if there is evidence of neurological involvement, intrathecal methotrexate and prednisone are indicated. As renal failure is quite common, chemotherapy might require a dose adjustment. Cyclosporine is often withheld until the patient’s renal function improves. After 8 weeks of treatment, either a bone marrow transplantation or a hematopoietic stem cell transplant is required in primary HS [1, 2, 37, 40].

In case of secondary syndrome, the management must be oriented to treat the underlying cause. When an autoimmune disease is present, immunosuppressive therapy must be initiated immediately; however, if there is an infectious agent involved (like our patient with CMV), immunosuppressive treatment should be withheld until the infection is under control, unless the patient is critically ill and other options have to be considered [32]. Etoposide is especially effective in HBV as it eliminates infected T lymphocytes [48]. In patients with less severe symptoms, adjuvant antibiotics, steroids and intravenous immunoglobulins might be enough [49] (Fig. 3).
Marsh et al. [50] published a review of cases of patients treated with alemtuzumab that had not responded to standard treatment. An improvement in the survival rate was observed; however, the overall prognosis seemed to be worse.

Conclusion

HLH is a very rare syndrome but an important life-threatening condition. Laboratory findings and symptoms are not very specific, so it is essential to learn how to suspect it in order to make an early diagnosis and stop its fatal course. It could be deduced that this patient may have been predisposed to developing HLH from the underlying undiagnosed connective tissue disease which was “unmasked” by the acute viral infection.

Compliance with ethical standards

Conflict of interest Leticia García-Montoya, Claudia Sáenz-Tenorio, Iustina Janta, Javier Menárguez, Indalecio Monteagudo and Esperanza Naredo declare that they have no conflict of interest. Javier López-Longo reports personal fees from Abbvie, Roche Farma, Bristol-Myers Squibb, Pfizer, UCB, MSD and Actelion, grants from Abbvie and GSK, outside the submitted work.

References

1. George MR (2014) Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med 5:69–86. doi:10.2147/JBM.S46255
2. Zhang L, Zhou J, Sokol L (2014) Hereditary and acquired hemophagocytic lymphohistiocytosis. Cancer Control 21:301–312
3. Henter JI, Elinder G, Söder O, Ost A (1991) Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand 80:428–435
4. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamsheh MA, Bosch X (2014) Adult haemophagocytic syndrome. Lancet 383:1503–1516. doi:10.1016/S0140-6736(13)60458-9
5. Stepp SE, Dufourcq-Lagelouse R, Kumar V (2015) Pillars article: perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999. 286: 1957–1959. J Immunol 194:5044–5046
6. Popko K, Górska E (2015) The role of natural killer cells in pathogenesis of autoimmune diseases. Cent Eur J Immunol 40:470–476. doi:10.5114/cej.2015.56971
7. Filipovich A, McClain K, Grom A (2010) Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transpl 16(1 Suppl):S82–S89. doi:10.1016/j.bbmt.2009.11.014
8. Krzewski K, Coligan JE (2012) Human NK cell lytic granules and regulation of their exocytosis. Front Immunol 3:335. doi:10.3389/fimmu.2012.00335
9. Janka GE (2012) Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med 63:233–246. doi:10.1146/annurev-med-041610-134208
10. Degar B (2015) Familial hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 29:903–913. doi:10.1016/j.hoc.2015.06.008
11. Zur Stadt U, Beutel K, Kolberg S, Schneppenheim R, Kabisch H, Janka G, Hennies HC (2006) Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum Mutat 27:62–68
12. Feldmann J et al (2003) Munc13-4 is essential for cytolytic granule fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115:461–473
13. Parekh C, Hofstra T, Church JA, Coates TD (2011) Hemophagocytic lymphohistiocytosis in children with chronic granulomatous disease. Pediatr Blood Cancer 56:460–462. doi:10.1002/pbc.22830
14. Ménasché G et al (2000) Mutations in RAB27A cause Griscelli syndrome associated with hemophagocytic syndrome. Nat Genet 25:173–176
15. Rubin CM et al (1985) The accelerated phase of Chediak-Higashi syndrome. An expression of the virus-associated hemophagocytic syndrome? Cancer 56:524–530

16. Arico M et al (2001) Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood 97:1131–1133

17. Li FY, Chaingne-Delalande B, Su H, Uzel G, Matthews H, Lenardo MJ (2014) XMEM disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood 123:2148–2152. doi:10.1182/blood-2013-11-538686

18. Enders A et al (2006) Lethal hemophagocytic lymphohistiocytosis in Hermansky–Pudlak syndrome type II. Blood 108:81–87

19. Sepulveda FE et al (2016) Polygenic mutations in the cytotoxicity pathway increase susceptibility to develop HLH immunopathology in mice. Blood 127:2113–2121. doi:10.1182/blood-2015-12-689690

20. Roe C, Bennett J, Zhang L, Chavez J, Shah B, Sokol L, Komrokji R (2015) Hemophagocytic lymphohistiocytosis in malignant hematolymphoid malignancies: uncommon but should not be forgotten? Clin Lymphoma Myeloma Leuk 15(Suppl):S147–S150. doi:10.1016/j.jclml.2015.03.009

21. Otrock ZK, Eby CS (2015) Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol 90:220–224. doi:10.1002/ajh.23911

22. Cattaneo C, Oberti M, Skert C, Passi A, Farina M, Re A, Tozzi P, Borlenghi E, Rossi G (2016) Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients. Hematol Oncol. doi:10.1002/hon.2314

23. Atim-Oluk M (2013) Cytomegalovirus associated haemophagocytic lymphohistiocytosis in the immunocompetent adult managed according to HLH-2004 diagnostic using clinical and serological means only. Eur J Microbiol Immunol (Bp). doi:10.1556/EuMI.3.2013.1.12

24. Presti MA, Costantino G, Della Torre A, Belvedere A, Ciacco A, Fries W (2011) Severe CMV-related pneumonia complicated by the hemophagocytic lymphohistiocytic (HLH) syndrome in quiescent Crohn’s colitis: harmful cure? Inflamm Bowel Dis. doi:10.1111/tid.12296

25. Casals M, BIOGEAS Study Group (2016) Infection is the major diagnostic and therapeutic challenge! Indian J Hematol Blood Transfus. doi:10.1007/s12288-014-0366-4

26. Cetica V et al (2016) Genetic predisposition to hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med 10:387–392. doi:10.1177/1526952815588943

27. Cattaneo C, Oberti M, Skert C, Passi A, Farina M, Re A, Tozzi P, Borlenghi E, Rossi G (2016) Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients. Hematol Oncol. doi:10.1002/hon.2314

28. Atim-Oluk M (2013) Cytomegalovirus associated haemophagocytic lymphohistiocytosis in the immunocompetent adult managed according to HLH-2004 diagnostic using clinical and serological means only. Eur J Microbiol Immunol (Bp). doi:10.1556/EuMI.3.2013.1.12

29. Presti MA, Costantino G, Della Torre A, Belvedere A, Ciacco A, Fries W (2011) Severe CMV-related pneumonia complicated by the hemophagocytic lymphohistiocytic (HLH) syndrome in quiescent Crohn’s colitis: harmful cure? Inflamm Bowel Dis. doi:10.1111/tid.12296

30. Saidi W et al (2015) Hemophagocytic lymphohistiocytosis: an unusual complication of leprosy. Int J Dermatol 54:1054–1059. doi:10.1111/ijd.12792

31. Dhotre R et al (2003) Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. doi:10.1002/art.11368

32. Kumakura S, Murakawa Y (2014) Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheumatol 66:2297–2307. doi:10.1002/art.38672

33. Granata G, Didona D, Stifano G, Feola A, Granata M (2015) Macrophage activation syndrome as onset of systemic lupus erythematosus: a case report and a review of the literature. Case Rep Med. doi:10.1155/2015/294041

34. Bae CB, Jung JY, Kim HA, Sub CH (2015) Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients. Medicine (Baltimore) 94:e451. doi:10.1097/MD.0000000000000451

35. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamash A, Bosch X (2014) Adult haemophagocytic syndrome. Lancet 383:1503–1516. doi:10.1016/S0140-6736(13)61048-X

36. Pagel J et al (2012) Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5). Blood 119:6016–6024. doi:10.1182/blood-2011-12-398958

37. Schram AM, Berliner N (2015) How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood 125:2908–2914. doi:10.1182/blood-2015-01-551622

38. Gratton SM, Powell TR, Theeler BJ, Hawley JS, Amjad FS, Torratare C (2015) Neurological involvement and characterization in acquired hemophagocytic lymphohistiocytosis in adulthood. J Neurol Sci 357:136–142. doi:10.1016/j.jns.2015.07.017

39. Castillo L, Carrillo J (2009) Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med 10:387–392. doi:10.1177/1526952815588943

40. Niece JA, Rogers ZR, Ahmad N, Langerman AM, McClain KL (2010) Hemophagocytic lymphohistiocytosis in Texas: observations on ethnicity and race. Pediatr Blood Cancer 54:424–428. doi:10.1002/pbc.22339

41. Valade S et al (2015) Coagulation disorders and bleedings in critically ill patients with hemophagocytic lymphohistiocytosis. Medicine (Baltimore) 94:e1692. doi:10.1097/MD.0000000000001692

42. Lim SH et al (2016) Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis. Ann Hematol 95:325–335. doi:10.1007/s00277-015-2523-8

43. Nordic R, Allen CE, Weitzman S, Filipovich AH, McClain KL (2011) How I treat hemophagocytic lymphohistiocytosis. Blood 118:4041–4052. doi:10.1182/blood-2011-03-278127

44. Cetica V et al (2016) Genetic predisposition to hemophagocytic lymphohistiocytosis: report on 500 patients from the Italian registry. J Allergy Clin Immunol 137(188–196):e4. doi:10.1016/j.jaci.2015.06.048

45. Popko K et al (2016) Impairment of immune function in children with familial hemophagocytic lymphohistiocytosis. Adv Exp Med Biol 912:21–31. doi:10.1007/978-94-007-5894-2_10

46. Wang Y et al (2014) Genetic features of late onset primary hemophagocytic lymphohistiocytosis in adolescence or adulthood. PLoS ONE 9:e107386. doi:10.1371/journal.pone.0107386

47. Henter JI et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131
48. La Rosée P (2015) Treatment of hemophagocytic lymphohistiocytosis in adults. Hematol Am Soc Hematol Educ Program 2015:190–196. doi:10.1182/asheducation-2015.1.190
49. Rajajee S, Ashok I, Manwani N, Rajkumar J, Gowrishankar K, Subbiah E (2014) Profile of hemophagocytic lymphohistiocytosis; efficacy of intravenous immunoglobulin therapy. Indian J Pediatr 81:1337–1341. doi:10.1007/s12098-014-1461-0
50. Marsh RA et al (2013) Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 60:101–109. doi:10.1002/pbc.24188